Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Recurrent Polymorphic Post-Transplant Lymphoproliferative Disorder: early-phase trial registry
1 of 3 indexed Recurrent Polymorphic Post-Transplant Lymphoproliferative Disorder trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #5,209 of 28,707 conditions by registered trial count.
3 US clinical trials · 1 currently recruiting · #5,209 of 28,707 conditions by registered trial count
Recurrent Polymorphic Post-Transplant Lymphoproliferative Disorder: 3 US clinical trials tracked, 1 recruiting.
Recurrent Polymorphic Post-Transplant Lymphoproliferative Disorder is the subject of 3 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is Timothy Voorhees, running 1 of these trials.
Enrollment posture brief
Registry condition recurrent-polymorphic-post-transplant-lymphoproliferative-disorder
OPEN 1 | RECR 33% | LATE 0 | EARLY 3 | RANK #5209 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Adherence, Treatment (33% recruiting · 6 trials)
Recurrent Polymorphic Post-Transplant Lymphoproliferative Disorder lists 1 open slots (33% of 3 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Recurrent Polymorphic Post-Transplant Lymphoproliferative Disorder on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Recurrent Polymorphic Post-Transplant Lymphoproliferative Disorder is recruiting below its size-band peers.
1 of 3 indexed trials (33.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
3 total, page 1 of 1
Epcoritamab for the Treatment of Relapsed or Refractory Post Transplant Lymphoproliferative Disorders
Timothy Voorhees
NCT06672705
Epcoritamab and Lenalidomide in Treating Patients With Refractory or Relapsed Immunodeficiency-Related Large B-Cell Lymphoma
Northwestern University
NCT06723457
Rituximab and LMP-Specific T-Cells in Treating Pediatric Solid Organ Recipients With EBV-Positive, CD20-Positive Post-Transplant Lymphoproliferative Disorder
Children's Oncology Group
NCT02900976
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Recurrent Polymorphic Post-Transplant Lymphoproliferative Disorder records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Recurrent Polymorphic Post-Transplant Lymphoproliferative Disorder trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Recurrent Polymorphic Post-Transplant Lymphoproliferative Disorder page
3 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Recurrent Polymorphic Post-Transplant Lymphoproliferative Disorder trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Timothy Voorhees sponsors the most Recurrent Polymorphic Post-Transplant Lymphoproliferative Disorder trials on record, review their full trial history before evaluating a specific study. See Timothy Voorhees's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Recurrent Polymorphic Post-Transplant Lymphoproliferative Disorder condition card totals 3 registered trials; most-linked intervention Epcoritamab; top US site state Missouri. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.